Merck Targets $70B+ Revenue by Mid-2030s as Keytruda Combo Doubles Response Rates
MRK sits 88% above its 52-week low of $77.58.
Summary
Merck projects human health revenue above $70B by the mid-2030s, driven by portfolio shift and new launches. Keytruda plus INBRX-106 showed 48.3% confirmed objective response rate versus 26.5% for Keytruda alone, with median PFS of 9.6 months versus 4.9 months. This is the first disclosure of these specific long-term revenue targets and combination efficacy data. The data supports Keytruda's expansion beyond current indications and reinforces the pipeline's growth potential. Watch for further updates on INBRX-106 development and regulatory filings.
At the time of this announcement, MRK was trading at $145.75 on NYSE in the Life Sciences sector, with a market capitalization of approximately $355.1B. The 52-week trading range was $77.58 to $156.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.